by The human microbiome refers to the total genetic material contained within the microorganisms that reside in our bodies, including bacteria, viruses, fungi and protozoa. Human microbiome therapeutics aim to restore balance within the human microbiome, by modulating the composition and metabolic output of gut microflora. Human microbiome diagnostics help understand the role of our microbiome in various health conditions like irritable bowel syndrome, obesity and diabetes.
The global Human Microbiome Market is estimated to be valued at US$ 592.3 million in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2027, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancing Research on Microbiome–Gut Health Interactions: Research is increasingly demonstrating the intricate relationships between the gut microbiome and various aspects of human health and disease. Studies exploring how changes in gut microbiome composition influence metabolism, obesity, digestion and immune function are propelling microbiome diagnostics and therapeutics development. This growing understanding of microbiome-gut-brain interactions and gut-lung axis is driving opportunities in developing microbiome modulating drugs, probiotics and personalized microbiome-based diagnostics and monitoring tools over the forecast period.
SWOT Analysis
Strength: The human microbiome market has a wide research potential as microbiome affects various fields including therapeutics, nutrition, and personal care.
Weakness: Limited understanding of the human microbiome and complexity associated with analysis of microorganisms pose challenges.
Opportunity: Growth opportunities exist in developing microbiome-based therapeutics, diagnostics, and testing applications to treat various diseases.
Threats: Stringent regulations for microbiome-based products and ethical issues related to genetic modification of microbes are major threats.
Key Takeaways
The Global Human Microbiome Market Size is expected to witness high growth.
North America currently dominates the market due to presence of key players and rising R&D activities for microbiome-based therapies. The Asia Pacific region is expected to grow at the fastest pace during the forecast period owing to increasing government funding for research.
Key players operating in the human microbiome market include Seres Therapeutics, Synthetic Biologics Inc., Vedanta Biosciences Inc., Second Genome and Enterome Bioscience. These players are focusing on developing novel microbiome-based therapies and tests to target various disease indications including immuno-oncology, metabolic disorders, and women’s health.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile itHuman Microbiome Market
